NICE recommends CINQAERO® (reslizumab) for the treatment of severe eosinophilic asthma
admin 21st July 2017 Uncategorised 0Teva Pharmaceutical Industries
More: NICE recommends CINQAERO® (reslizumab) for the treatment of severe eosinophilic asthma
Source: MDlinx